Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain DVAX message board posts where the ticker symbol DVAX has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest DVAX SEC Filings

Filings Format Description Filing Date File/Film Number
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001564590-19-017985 (34 Act)  Size: 8 MB
2019-05-09 001-34207
19810648
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001564590-19-017971 (34 Act)  Size: 135 KB
2019-05-09 001-34207
19810482
DEF 14A  Documents Other definitive proxy statements
Acc-no: 0001193125-19-113381 (34 Act)  Size: 1 MB
2019-04-22 001-34207
19759549
CT ORDER  Documents Confidential treatment order
Acc-no: 9999999997-19-002963 (34 Act)  Size: 94 KB
2019-04-17 001-34207
19751819
8-K  Documents Current report, items 2.03 and 9.01
Acc-no: 0001564590-19-008271 (34 Act)  Size: 46 KB
2019-03-18 001-34207
19688310
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-19-015262 Size: 6 KB
2019-03-01
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-19-015257 Size: 9 KB
2019-03-01
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-19-015253 Size: 6 KB
2019-03-01
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-19-015249 Size: 17 KB
2019-03-01
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-19-015245 Size: 6 KB
2019-03-01
More DVAX SEC Filings


Related news from
Mon, 20 May 2019
04:29:01 +0000
Edited Transcript of DVAX earnings conference call or presentation 8-May-19 8:30pm GMT
Q1 2019 Dynavax Technologies Corp Earnings Call
Fri, 10 May 2019
13:14:00 +0000
Hopeful Signs for These 2 Small Biotech Stocks
A non-biotech investor would think FDA approval is the biggest hurdle for most small biotech companies and would be rewarded by the market. This is why so many small biotech stocks frequently decline in the quarters following the initial euphoria of FDA approval. This is why initial drug rollouts are usually slower and consume more cash that investors expect after the FDA green light is granted.
Thu, 09 May 2019
18:08:00 +0000
Why Dynavax Technologies Stock Is Soaring Today
Heplisav-B's commercial launch is starting to ramp up.
Thu, 09 May 2019
17:33:33 +0000
Is Dynavax Technologies Corporation (DVAX) A Good Stock To Buy?
How do we determine whether Dynavax Technologies Corporation (NASDAQ:DVAX) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows […]
Thu, 09 May 2019
01:23:49 +0000
Dynavax Technologies Corp (DVAX) Q1 2019 Earnings Call Transcript
DVAX earnings call for the period ending March 31, 2019.
Wed, 08 May 2019
23:45:11 +0000
Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 7.46% and -3.94%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Wed, 08 May 2019
22:35:47 +0000
Dynavax Technologies: 1Q Earnings Snapshot
The Berkeley, California-based company said it had a loss of 62 cents per share. The biopharmaceutical company posted revenue of $5.8 million in the period. Dynavax Technologies shares have fallen 29% ...
Wed, 08 May 2019
20:05:00 +0000
Dynavax Announces First Quarter 2019 Financial Results
First quarter 2019 HEPLISAV-B® net product revenue of $5.6 millionConference call to be held today at 4:30 p.m. ET/1:30 p.m. PT BERKELEY, Calif., May 08, 2019 -- Dynavax.
Wed, 08 May 2019
18:30:00 +0000
Dynavax Technologies Corp. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 8, 2019 / Dynavax Technologies Corp. (NASDAQ: DVAX ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 8, 2019 at 4:30 PM ...
Thu, 02 May 2019
21:00:00 +0000
Dynavax Announces First Patient Enrolled in Study of HEPLISAV-B® in Adults With End-Stage Renal Disease
Dynavax Technologies Corporation (DVAX), a fully-integrated biopharmaceutical company focused on discovering, developing and commercializing novel vaccines and immuno-oncology therapeutics, today announced the enrollment of the first patient in the company’s open-label, single-arm study of HEPLISAV-B in adults with end-stage renal disease who are initiating or undergoing hemodialysis. “Although vaccination to prevent hepatitis B infection has been standard practice for decades for dialysis patients and healthcare workers, there remains a need to provide improved overall protection safely through a greater and more durable antibody response,” said Robert Janssen, M.D., chief medical officer of Dynavax. This open-label, single arm study will evaluate HEPLISAV-B in adults with end-stage renal disease who are initiating or undergoing hemodialysis.
Wed, 01 May 2019
14:33:02 +0000
Analysts Estimate Dynavax Technologies (DVAX) to Report a Decline in Earnings: What to Look Out for
Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Thu, 25 Apr 2019
20:05:00 +0000
Dynavax Technologies to Report First Quarter 2019 Financial Results and Host Conference Call on May 8
BERKELEY, Calif., April 25, 2019 -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel.
Thu, 18 Apr 2019
20:05:00 +0000
Dynavax to Present Data on Toll-like Receptor 9 Agonist SD-101 at the ASCO Annual Meeting 2019
BERKELEY, Calif., April 18, 2019 -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel.
Sat, 06 Apr 2019
14:42:56 +0000
Investors Who Bought Dynavax Technologies (NASDAQ:DVAX) Shares Three Years Ago Are Now Down 66%
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But l...
Wed, 03 Apr 2019
14:02:41 +0000
After inking lease with cancer-fighting company, this new East Bay biotech project is full
EmeryStation West is the latest building in Wareham Development's 2 million-square-foot complex in Emeryville.
Tue, 02 Apr 2019
17:00:00 +0000
Dynavax Presents Phase 1b Data on Inhaled DV281 TLR9 Agonist at the 2019 AACR Annual Meeting
Dynavax Technologies Corporation (DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, today announced results from the ongoing Phase 1b clinical study evaluating the safety of DV281, a novel toll-like receptor (TLR) 9 agonist in combination with nivolumab in patients with advanced or metastatic non-small cell lung cancer (NSCLC). The results were presented today in a poster session at the 2019 American Association for Cancer Research (AACR) Annual Meeting 2019 (Exhibit Hall B, Poster Section 17, Poster Board Number: #18, 1:00 pm. – 5:00 p.m. ET).
Tue, 02 Apr 2019
11:30:37 +0000
The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 1) Abbott Laboratories (NYSE: ABT ) AEterna Zentaris Inc. ...
Thu, 28 Mar 2019
20:05:00 +0000
Dynavax Announces European Medicines Agency Accepts Marketing Authorization Application for HEPLISAV-B® for Prevention of Hepatitis B in Adults
Dynavax Technologies Corporation (DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, today announced that the European Medicines Agency (EMA) has accepted the Company's Marketing Authorization Application (MAA) for review of HEPLISAV-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. This acceptance follows Dynavax's submission of the MAA on March 11 and marks the beginning of the regulatory review process for HEPLISAV-B in the European Union (EU). The outcome of the MAA review by the EMA is expected next year.
Thu, 21 Mar 2019
10:30:00 +0000
HLS Therapeutics Announces Q4 and Year-End 2018 Financial Results
HLS Therapeutics Announces Q4 and Year-End 2018 Financial Results
Wed, 20 Mar 2019
20:20:00 +0000
Dynavax to Present on Inhaled TLR9 Agonist DV281 at the AACR Annual Meeting 2019
BERKELEY, Calif., March 20, 2019 -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "At VF I have met some of the greatest givers from all walks of life and from all parts of the world. I thank each of them for sharing part of their life and knowledge with me." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2019, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards